Neurocrine Biosciences Inc
(NAS:NBIX)
$
139.51
-3.52 (-2.46%)
Market Cap: 14.12 Bil
Enterprise Value: 13.50 Bil
PE Ratio: 37.40
PB Ratio: 5.19
GF Score: 84/100 Neurocrine Biosciences Inc at Cowen HealthCare Conference Transcript
Mar 03, 2020 / 05:00PM GMT
Release Date Price:
$92.57
(-3.88%)
Philip M. Nadeau
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
All right. Well, welcome once again to Cowen and Company's 40th Annual Health Care Conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to conduct a fireside chat with Neurocrine Biosciences. These are truly exciting times for Neurocrine as INGREZZA is launching and doing quite well.
So we're happy to have with us Kevin Gorman, CEO; Kyle Gano, Chief Business Development and Strategy Officer, and Todd Tushla from IR. Guys, thanks for joining us.
Questions & Answers
Philip M. Nadeau
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Maybe, Kevin, we'll start with you. Could you give us a brief state of the company overview, what are the biggest strengths, biggest challenges? And what needs to happen to continue to drive outperformance over the next year or 2?
Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director
Sure, Phil.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot